The aim of the current study was to design an oral sustained release matrix tablet of metformin HCl and to optimize the drug release proˆle using response surface methodology. Tablets were prepared by non-aqueous wet granulation method using HPMC K 15M as matrix forming polymer. A central composite design for 2 factors at 3 levels each was employed to systematically optimize drug release proˆle. HPMC K 15M (X 1 ) and PVP K 30 (X 2 ) were taken as the independent variables. The dependent variables selected were ％ of drug released in 1 hr (rel 1 hr ), ％ of drug released in 8 hrs (rel 8 hrs ) and time to 50％ drug release (t 50％ ). Contour plots were drawn, and optimum formulations were selected by feasibility and grid searches. The formulated tablets followed Higuchi drug release kinetics and diŠusion was the dominant mechanism of drug release, resulting in regulated and complete release within 8 hrs. The polymer (HPMC K 15M) and binder (PVP K 30) had signiˆcant eŠect on the drug release from the tablets ( p＜0.05). Polynomial mathematical models, generated for various response variables using multiple linear regression analysis, were found to be statistically signiˆcant ( p＜0.05). Validation of optimization study, performed using 8 conˆrmatory runs, indicated very high degree of prognostic ability of response surface methodology, with mean percentage error (±S.D.) 0.0437± 0.3285. Besides unraveling the eŠect of the 2 factors on the in vitro drug release, the study helped inˆnding the optimum formulation with sustained drug release.
INTRODUCTION
Introduction of matrix tablet as sustained release (SR) has given a new breakthrough for novel drug delivery system (NDDS) in theˆeld of pharmaceutical technology. It excludes complex production procedures such as coating and pelletization during manufacturing and drug release rate from the dosage form is controlled mainly by the type and proportion of polymer used in the preparations. Hydrophilic polymer matrix is widely used for formulating an SR dosage form. 1 4) Hydroxypropyl methyl cellulose (HPMC) is the widely used hydrophilic polymer to prolong drug release due to its rapid hydration, good compression and gelling characteristics along with its ease of use, availability and very low toxicity. It regulates the release of drug by controlling the swelling and crosslinking. 5, 6) In the development of a sustained release tablet dosage form, an important issue is to design an optimized formulation with an appropriate dissolution rate in a short time period and minimum number of trials. Many statistical experimental designs have been recognized as useful techniques to optimize the process variables. For this purpose, a computer based optimization technique with a response surface methodology (RSM) utilizing a polynomial equation has been widely used. 7 13) DiŠerent types of RSM designs include 3-level factorial design, central composite design (CCD), Box-Behnken design and D-optimal design. Response surface methodology (RSM) is used when only a few signiˆcant factors are involved in optimization. The technique requires minimum experimentation and time, thus proving to be far more eŠective and cost-eŠective than the conventional methods of formulating sustained release dosage forms. Metformin HCl is an orally administered biguanide, which is widely used in the management of type-2 diabetes, a common disease that combines defects of both insulin secretion and insulin action. 14) It improves hepatic and peripheral tissue sensitivity to insulin without the problem of serious lactic acidosis commonly found with its analogue, phenformin. It has three diŠerent actions: it slows the absorption of sugar in our small intestine; it also stops our liver from converting stored sugar into blood sugar; and it helps our body use our natural insulin more e‹cient-ly. It is a hydrophilic drug and is slowly and incompletely absorbed from the gastrointestinal tract and the absolute bioavailability of a single 500 mg dose is reported to be 50 60％. 15) An obstacle to more successful use of metformin therapy is the high incidence of concomitant gastrointestinal symptoms, such as abdominal discomfort, nausea, and diarrhea that especially occur during the initial weeks of treatment. Also the compound has relatively short plasma elimination half-life of 1.5 to 4.5 hrs. 16, 17) Side eŠects and the need for administration two or three times per day when larger doses are required can decrease patient compliance. Sustained release formulations that would maintain plasma levels of drug for 8 to 12 hrs might be su‹cient for once daily dosing for metformin. SR products are needed for metformin to prolong its duration of action and to improve patient compliance. 15, 18) Fiona et al. 19) of Colorcon Ltd., UK has described the method for preparation of metformin HCl 500 mg extended release tablet by direct compression method. But in commercial scale it creates problem of powder ‰ow ability from hoper to compression machine followed by weight variation, content uniformity, hardness and friability due to poor inherent compressibility of metformin HCl. SR microcapsules of metformin by ethylcellulose had been described by Balan et al. 17) where metformin gave in vitro release for up to 22 hrs. But preparation of microcapsules in commercial scale and optimization of drug release rate is troublesome. Defang et al. 16) had described the bilayer matrix tablet and osmotic pump tablet consisting metformin and glipizide both as SR form. The aim of this investigation was to develop a sustained release matrix tablet of metformin HCl using HPMC K 15M by non-aqueous wet granulation method and optimize the formulation using RSM.
MATERIALS AND METHODS

Materials
Metformin HCl was received from Deys Medical, Kolkata, India as donate sample.
Hydroxy propyl methyl cellulose (HPMC K 15M) was a gift sample received from M/S Colorcon Asia Pvt. Ltd., Mumbai, India. Microcrystalline cellulose (MCC) and PVP K 30 (polyvinyl pyrrolidone K 30) were purchased from S. D. Fine Chemicals Ltd., Mumbai, India. Magnesium stearate and talc were procured from Mohanlal Dayaram and Company, Hyderabad. All other chemicals/reagents used were of analytical grade, except for those used in HPLC analysis, which were of HPLC grade.
Preparation of Sustained Release Matrix Tablets Table 1 enlists the composition of diŠerent trial formulations prepared using varying amounts of HPMC K 15M as release controlling polymer and PVP K 30 as binder along withˆxed quantity of talcum and magnesium stearate as lubricant. MCC was used aŝ ller. HPMC K 15M polymer at diŠerent ratio was blended with metformin HCl, MCC and PVP K 30 in a planetary mixer for 5 mins after passing all the materials through a mesh (1150 mm). Thereafter the powders were granulated with isopropyl alcohol, sieved using a mesh (100 mm) and dried at 50°C for about 2 hrs with residual moisture content of 2 to 3％ w/w. The dried granules were sized by a mesh (250 mm) and mixed with magnesium stearate and talc for 2 mins. All granules were weighedˆnally to adjust thê nal weight of individual tablet considering its loss during operational handling. Granules thus obtained were compressed into 1150 mg tablets to average hardness of 6 to 8 kg/sq.cm on an eight station rotary tablet machine (CIP Machineries Pvt. Ltd., Ahmedabad, India) with 19.5x8.9 mm caplet tooling at a rotational speed of 72 rpm.
Experimental Design A central composite design (CCD) with a＝1 was employed as per the standard protocol. 8, 11) The amounts of HPMC K 15M (X 1 ) and PVP K 30 (X 2 ) were selected as the factors, studied at 3 levels each. The central point (0, 0) was studied in quintuplicate. All other formulation and processing variables were kept invariant throughout the study. Table 2 summarizes an account of the 13 experimental runs studied, their factor combinations, and the translation of the coded levels to the experimental units employed during the study. ％ of drug released in 1 hr (rel 1 hr ) (Y 1 ), ％ of drug released in 8 hrs (rel 8 hrs ) (Y 2 ) and time to 50％ drug release (t 50％ ) (Y 3 ) were taken as the response variables.
Tablet Assay and Physical Evaluation 20 tablets were taken and crushed to powder with mortar and pestle. Exact amount of powder (average weight) was taken and diluted with methanol up to 200 ml of volumetric ‰ask. After sonication for 15 mins, solution wasˆltered through 0.45 mmˆlter paper. The total amount of drugs within the tablets was analyzed after appropriate dilution of test solution by using the HPLC method as described below against the reference solution of metformin pure powder prepared in the same procedure. Tablets were also evaluated for hardness (n＝10), friability (n＝10), weight variation (n＝20), and thickness (n＝10).
Drug Release Study
Drug release from 6 tablets of each formulation, in triplicate, was determined using the USP I (basket) apparatus (Electrolab, TDT 06P, USP XXIII) where 900 ml of 0.1 N HCl and phosphate buŠer of pH 6.8 were used as dissolution media maintained at 37°C (±0.5°C) at 100 rpm. The release rates from the tablets were conducted in a dissolution medium of 0.1 N HCl for 2 hrs and thereafter in phosphate buŠer of pH 6.8 for 6 hrs. 5 ml of aliquot were withdrawn at 1, 2, 4 and 8 hrs with replacement of fresh media. Solution samples were analyzed by high performance liquid chromatography (HPLC) method mentioned in earlier section. Drug release proˆles were drawn using MS-Excel software and the values of t 50％ were obtained by interpolation from Excel graph.
Drug Release Kinetics In order to propose a possible release mechanism, drug release from HPMC matrix tablets wasˆtted to the following equations:
Higuchi's 21) equation: Q＝K H t 1/2 (1) Where, Q is the amount of drug release at time t, and K H is the Higuchi rate constant. Koresmeyer et al.'s 20) 
Where, M t is the amount of drug released at time t, M ∞ is the amount of drug released after inˆnite time, M t /M ∞ is the fractional drug release percentage at time t, k is a constant related to the properties of the drug delivery system, and n is the release exponent indicative of the drug release mechanism.
Optimum Release Proˆle Optimum release proˆle for once-daily SR formulation was calculated by the following equation 22) using available pharmacokinetic data: 23) D t ＝Dose(1＋0.693×t/t 1/2 ) ( 3) Where, D t ＝total dose of drug; Dose＝dose of the immediate release part; t＝time (hr) during which the sustained release is desired (8 hrs); t 1/2 ＝half-life of the drug (3 hrs).
The optimum formulation was selected based on the above equation so that it could attain complete 
are the coe‹cients computed from the observed experimental response values of Y; and X 1 and X 2 are the coded levels of the independent variable(s). The terms X 1 X 2 and X 2 i (i＝1 to 2) represent the interaction and quadratic terms, respectively. Statistical validity of the polynomials was established on the basis of ANOVA provision in the Design Expert Software. Subsequently, the feasibility and grid searches were performed to locate the composition of optimum formulations. 13, 24) Two-dimensional (2-D) contour plots were constructed based on the model polynomial functions using Design Expert Software. These plots are very useful to see interaction eŠects on the factors on the responses.
Eight optimum checkpoints were selected based on the criteria from optimum formulation described earlier by intensive grid search, performed over the entire experimental domain, to validate the chosen experimental design and polynomial equations. The formulations corresponding to these checkpoints were prepared and evaluated for various response properties. Subsequently, the resultant experimental data of response properties were quantitatively compared with that of their predicted values. Also, linear regression plots between observed and predicted values of the response properties were drawn using MS-Excel, forcing the line through origin
RESULTS AND DISCUSSION
Drug Content and Physical Evaluation
The as- Table 3 . In the current study, the values of release rate exponent (n), calculated as per the equa- 20) ranged between 0.4993 and 0.5874 (Table 3) . For matrix tablets, an n value of near 0.5 indicates diŠusion control, and an n value of near 1.0 indicates erosion or relaxation control. Intermediate values suggest that diŠusion and erosion contribute to the overall release mechanism. 25, 26) In our experiments the results of n clearly indicated that the diŠusion is the dominant mechanism of drug release from these formulations. DiŠusion is related to transport of drug from the dosage matrix into the in vitro study ‰uid depending on the concentration of the hydrophilic polymer. As gradient varies, the drug is released, and the distance for diŠusion increases. This could explain why the drug diŠuses at a comparatively slower rate as the distance for diŠusion increases.
Total amount of metformin released from all the formulations up to 8 hrs ranged between 73.11％ and 100.21％ indicating incomplete drug release at higher concentration of HPMC K 15M as well as PVP K 30. Rate of drug release (until 8 hrs) tended to decrease with increase in the content of either HPMC or PVP K 30. This is in agreement with literatureˆndings 27, 28) that the viscosity of the gel layer around the tablet increases with increase in the hydrogel concentration, thus limiting the release of active ingredient. The gel formed during the penetration of dissolution media into the matrix structure, consists of closely packed swollen particles. With further increase in polymer amount, thicker gel forms inhibiting dissolution media penetration more strongly, resulting in signiˆcant reduction in the values of rel 8 hr indicating slower drug release.
The values of t 50％ enhanced markedly from 1.62 hrs, observed at low levels of both the variables, to as high as 3.92 hrs, observed at high levels of both the variables. Thisˆnding indicated considerable release retarding potential of the polymer and binder. Figure 1 exhibits the mean (±S.D.) cumulative metformin release (％) versus time proˆles obtained for various trial formulations, prepared as per CCD. The formulations with lower levels of polymer and binder exhibited initial burst in drug release. This result could be attributed to the dissolution of drug present initially at the surface of the matrices and rapid penetration of dissolution media to the matrix structure. However, the formulations showed little burst eŠect at higher polymer levels, ratifying better substance of drug release. Overall, all the formulations showed quite regulated drug release from 4 hrs onwards.
RSM Optimization Results Mathematical Modeling
Mathematical relationships generated using MLRA for the studied response variables are expressed as Eqs. 5 to 7. Vol. 127 (2007) per the provision of Design Expert Software ( Table  4) . Using 5％ signiˆcance level, a model is considered signiˆcant if the p value (signiˆcance probability value) is less than 0.05. From the p values presented in Table 4 , it can be concluded that for all four responses, the cross-product contribution (X 1 X 2 ) and quadratic contributions (X The polynomial equations comprise the coe‹cients for intercept,ˆrst-order main eŠects, interaction terms, and higher order eŠects. The sign and magnitude of the main eŠects signify the relative in‰uence of each factor on the response. The values obtained for main eŠects of each factor from Eqs. 5 to 7 reveal that HPMC K 15M, individually, has rather more pronounced eŠect on all response values. At a given set factor levels, however, these higher-order polynomials yield results as the net eŠect of all the coe‹cient terms contained in the polynomial.
Response Surface Analysis Figures 2, 3 and 4 are the two-dimensional contour plots for the studied response properties viz rel 1 hr , rel 8 hr and t 50％ . Figure 2 exhibits that rel 1 hr vary in a nonlinear fashion, but in a descending pattern with an increase in the amount of polymer and binder. It also shows that HPMC K 15M has a comparatively greater in‰uence on the response variable than PVP K 30.
In contrast to the results of drug release in 1 hr, contour plot for drug release in 8 hrs (Fig. 3) reveal that rel 8 hr varies in somewhat linear fashion with in- crease of polymer and binder contents. However, the eŠect of HPMC K 15M seems to be more pronounced as compared with that of PVP K 30. Figure 4 exhibits that time to 50％ drug release (t 50％ ) vary in a nonlinear manner, but in a ascending pattern with an increase in the amount of each variables. But at the higher amount of HPMC K 15M and PVP K 30 the contour lines turned to be linear.
Validation of RSM Results
For all of the 8 checkpoint formulations, the results of the physical evaluation and tablet assay were found to be within limits. Table 5 
CONCLUSION
Controlled drug release following Higuchi kinetics attained in the current study indicates that the hydrophilic matrix tablet of metformin, prepared using HPMC K 15M and PVP K 30, can successfully be employed as once-a-day oral controlled release drug delivery system. Both the polymer and binder plays major role for the sustained release of metformin. However, appropriate balancing between various levels of the polymer and binder may contribute better results. High degree of prognosis obtained using RSM corroborates that a 2-factor CCD is quite e‹cient in optimizing drug delivery systems that exhibit nonlinearity in response(s).
